Specialty Pharmacy

Regulatory action could help patients with Hunter syndrome who have cognitive and behavioral complications and often do not have an effective treatment crossing the blood-brain barrier.

Backed by positive results in multiple clinical trials, a new drug application (NDA) has been submitted for relacorilant for consideration by the FDA.

Early diagnosis of chronic kidney disease (CKD) can help optimize treatment and manage the disease to prevent further decline.

Pharmacy students can provide education, patient advocacy, and medication access.

New medications like glucagon-like peptide-1 agonists and resmetirom show promise in reversing fatty liver disease and preventing progression.

Pharmacists should be aware of the impacts that anemia in patients being treated for cancer has on daily activities and overall quality of life.

Adherence to thiopurine medications after 6 months of use was 87.9% under direct pharmacist care but 65.7% under general practitioner guidance.

Treatment options may include treating the anemia with blood transfusions, androgen therapy, thalidomide, and other medications.

Pharmacists can educate patients on controlling risk factors and stay up-to-date on emerging therapies like SGLT2 inhibitors and finerenone that can slow disease progression.

The potential treatments include ivermectin, methylene blue, glucagon-like peptide-1 receptor agonists, and low-dose naltrexone.

The disparity highlights opportunities for pharmacists to get involved and address health disparities.

Gecacitinib is a novel inhibitor targeting both JAK and ACVR1.

Adoption barriers include insurance coverage, patient and provider education, and regulatory hurdles that require aligned initiatives across stakeholders.

Pharmacists can significantly improve chronic obstructive pulmonary disease (COPD) management by promoting non-pharmacological interventions.

Despite the explosion of public interest in these drugs, ongoing shortages and debates over compounding made access difficult.

Currently available for prescription in the United States, vibegron is now the first and only β3 agonist FDA approved to treat patients living with OAB and being treated for BPH.

Concizumab-mtci is a subcutaneous, monoclonal antibody designed to achieve hemostasis in all hemophilia types.

The medication, glepaglutide, is in development for the treatment of adults with short bowel syndrome with intestinal failure who are dependent on parenteral support.

The approval comes after clinical trial results in which vanzacaftor/tezacaftor/deutivacaftor (Alyftrek; Vertex Pharmaceuticals) demonstrated superiority compared with elexacaftor/tezacaftor/ivacaftor and ivacaftor (Trikafta; Vertex Pharmaceuticals).

Vanzacaftor/tezacaftor/deutivacaftor (Alyftek) also received approval for the treatment of cystic fibrosis in people 6 years and older who have at least 1 F508del mutation.

Setmelanotide is indicated to reduce excess body weight and maintain weight reduction long-term for patients with syndromic or monogenic obesity due to Bardet-Biedl syndrome.

Compounding pharmacies have a 60- to 90-day grace period to complete production as it continues to monitor supply and demand.

Compounding pharmacies play a vital role in meeting the unique needs of patients, but pharmacists must adhere to strict safety standards and regulations.

The rare genetic disease is a severe hypertriglyceridemia that can lead to potentially life-threatening acute pancreatitis.

The evolving regulatory policies around biosimilar interchangeability is crucial for driving successful biosimilar adoption in the marketplace.

Pharmacy errors can happen due to manual processes, but they can be mitigated through adoption of automated IV workflow technology and comprehensive compounding records.

Standardizing observational competencies and utilizing technology to improve compounding accuracy can ensure safety and quality of compounded medications.

The tool is designed to address the nocebo effect, which was a concern of prescribers and other health care professionals.

Based on positive results from the HERCULES trial, the new designation will allow for more thorough regulatory review and development of the multiple sclerosis treatment.